At a CAGR of 15.65%, Natural Killer Cells Therapeutics Market to Reach US$ 5.1 Billion by 2027 |

According to IMARC Group's latest report, titled "Natural Killer Cells Therapeutics Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2022-2027", the global natural killer cells therapeutics market reached a value of US$ 2.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2027, exhibiting a CAGR of 15.65% during 2022-2027.

Natural killer (NK) cells refer to granular lymphocytes that play essential roles in immunity against viruses and in the immune surveillance of tumors. NK cells therapeutics targets numerous pathogenic antigens with effective cytotoxicity and reduces the cytokine storm risk. These entities can be produced from several varieties of sources without depending on patient-specific immune cells. Presently, various strategies are developing, such as ex-vivo pre-conditioning with cytokines or small molecular drugs and engineering a chimeric antigen receptor (CAR) NK, which is improving the efficacy of NK cells therapeutics. 

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Download a free sample report to get a detailed overview of the report: https://www.imarcgroup.com/natural-killer-cells-therapeutics-market/requestsample

The rising focus among researchers on maximizing the therapeutic effects of allogeneic NK cells through robust expansion, enhanced targeting, and extended persistence of potent immune cells is among the key factors stimulating the natural killer cells therapeutics market. Besides this, the inflating number of individuals with cancer, infectious diseases, and liver disorders is also propelling the global market. Additionally, the rising prevalence of unhealthy dietary patterns and lack of physical activities among consumers, the growing air pollution levels, and the increasing number of individuals consuming alcohol and tobacco products are further fueling the market growth.

Apart from this, the development of novel methods and technologies by health companies to boost the immune responses through allogeneic and off-the-shelf NK cell-based therapies is acting as another significant growth-inducing factor. Furthermore, the elevating number of clinical studies focusing on tumor-targeted antibody strategies to enhance the therapeutic benefits of NK-cell-based therapy while minimizing risks and toxicities involved is also catalyzing the market growth. Moreover, the escalating availability of financial schemes for cancer patients by the governing bodies of numerous countries is expected to positively influence the natural killer cells therapeutics market over the forecasted period.

Based On Therapeutics:

NK Cell Therapies
NK Cell Directed Antibodies 

Based On Application:

Cancer 
Gastrointestinal Diseases
Immunoproliferative Disorders
Others

Based On End User:

Hospitals
Research Centers and Institutes 
Others

Region:

North America (United States, Canada)
Europe (Germany, France, United Kingdom, Italy, Spain, Others)
Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)

Competitive Landscape with Key Players:

Affimed GmbH
Bristol-Myers Squibb Company
Fate Therapeutics
Fortress Biotech Inc.
Glycostem Therapeutics
Innate Pharma S.A.
Kuur Therapeutics Inc
Athenex Inc
Nkarta Inc.
Takeda Pharmaceutical Company Limited
Ziopharm Oncology Inc.

Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/natural-killer-cells-therapeutics-market

Key highlights of the report:                                                           

Market Performance (2016-2021)
Market Outlook (2022-2027)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 30 N Gould St Ste R
City: Sheridan
State: WY
Country: United States
Website: https://www.imarcgroup.com/

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.